Pliant Therapeutics
PLRX
61 hedge funds and large institutions have $648M invested in Pliant Therapeutics in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
11% more funds holding
Funds holding: 55 → 61 (+6)
2% more capital invested
Capital invested by funds: $635M → $648M (+$12.5M)
0.81% more ownership
Funds ownership: 79.56% → 80.37% (+0.81%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.31M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.65M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.52M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
+$602K |
| 5 |
Goldman Sachs
New York
|
+$453K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$3.44M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.51M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.17M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$580K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$566K |
PLRX Hedge Fund Activity: Q4 2020 in Review
61 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2020, worth a combined $648M — up 2% from $635M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PLRX positions and 5 closed out — a net gain of 7 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $9.31M. The largest seller was Woodline Partners, exiting entirely with an estimated $3.44M sold.
- 61 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2020, up from 55 in Q3 2020.
- Funds reported $648M of Pliant Therapeutics stock for Q4 2020, up 2% quarter-over-quarter.
- 12 funds opened new Pliant Therapeutics positions in Q4 2020 and 5 closed out, a net change of +7 holders.
- The largest Pliant Therapeutics buyer in Q4 2020 was BlackRock, an estimated $9.31M added.
- The largest Pliant Therapeutics seller in Q4 2020 was Woodline Partners, an estimated $3.44M sold.
Based on aggregated 13F filings for Q4 2020.